Anti-CCL2 therapeutic antibody (Pre-made Carlumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-094-1mg	1mg	3090
GMP-Bios-ab-094-10mg	10mg	21890
GMP-Bios-ab-094-100mg	100mg	148000
GMP-Bios-ab-094-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-CCL2 therapeutic antibody (Pre-made Carlumab biosimilar,Whole mAb)
INN Name	Carlumab
Target	CCL2
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	4dn3:HL/4dn4:HL
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	MorphoSys;Janssen Biotech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours
Development Tech	Human Phage Display